Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
Lung cancer is the most common cancer worldwide and is the leading cause of cancer death in Western countries [1]. Non-small cell lung cancer (NSCLC) is the most common form (80 –85%) of lung cancers. At the time of diagnosis, most patients with NSCLC present with metastatic or advanced disease [2]. Activating mutations of the gene encoding the tyrosine kinase of the epidermal growth factor receptor (EGFR) are present in about 10% of NSCLC patients in France [3] and more than 90% of these mutations are reported in exons 19 − 21 [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Jean Bernard Auliac, Maurice P érol, David Planchard, Isabelle Monnet, Marie Wislez, Hélène Doubre, Florian Guisier, Eric Pichon, Laurent Greillier, Bénédicte Mastroianni, Chantal Decroisette, Roland Schott, Sylvestre Le Moulec, Jennifer Arrondeau, A Source Type: research
More News: Cancer | Cancer & Oncology | France Health | Genetics | Lung Cancer | Non-Small Cell Lung Cancer